Virtual Reality and Varenicline for Nicotine Addiction
This study is looking at how a medication called varenicline (Chantix) affects nicotine addiction, specifically how it changes your attention to smoking cues. Researchers want to see if virtual reality (VR) can help measure these changes. You would be one of 200 daily tobacco cigarette users, aged 22 or older, from the San Diego area. You would receive either varenicline (1mg twice daily) or a placebo (an inactive pill). The study will measure changes in your attention to smoking cues using VR before and after treatment, and also track your nicotine cravings and short-term smoking behaviors for about 30 days. The goal is to understand how varenicline works and if VR can be a useful tool to measure its effects.
- Study design
- This is an interventional study involving 200 participants who will be randomly assigned to receive either varenicline or a placebo.
- What's involved
- You would have in-person sessions at baseline and after about 8 days of treatment, with mobile and phone assessments for up to 30 days after the second in-person visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for short-term nicotine use behaviors for an average of 30 days after the post-treatment assessment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kelly Courtney, Ph.D. · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Virtual Reality Attentional Bias (VR-AB) pre- and post-treatmentduring each in-person session, at baseline and on average 8 days post baseline assessment
Eye gaze fixation time to active versus neutral cues from the \"NTP Cue VR Paradigm\"
- Nicotine cravingduring each in-person session, at baseline and on average 8 days post baseline assessment
Assessed via the Tobacco Craving Questionnaire - Short-Form
- Nicotine cravingthrough study completion, an average of 30 days
Assessed via visual analogue scales (VR paradigm and mobile surveys)
- Nicotine use episodesduring each in-person session, at baseline and on average 8 days post baseline assessment
Assessed via the Timeline Followback
- Nicotine use episodesthrough study completion, an average of 30 days
Assessed via participant fill-in on mobile surveys